University of Tennessee Medical Center

Cancer Institute

Knoxville, TN

Sorting 2 by

Accepting patients

SubQSA

A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

iMMagine-3

A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Randomization
  • Phase 3